The expanded collaboration will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026. The last close places the company's stock about $3.98 off its 52 week high of $13.36 and $1.7 above the 52 week low of $7.68. Similarly, the company's Director Samuels Theodore R. II on 2017-08-02 Buy 6000 shares of the company at a price of $55.94. It has underperformed by 39.89% the S&P500. HighPoint Advisor Group LLC now owns 21,659 shares of the biopharmaceutical company's stock valued at $1,334,000 after buying an additional 8,372 shares during the last quarter. Bristol-Myers Squibb's dividend payout ratio is 61.42%. Whereas, in last 21 trading days (one month) was surged -6.59% and isolated positively in last 63 trading days (quarter) of 5.39%.
About 239,637 shares traded. It has underperformed by 5.42% the S&P500.
Investors of record on Friday, October 6th were issued a $0.39 dividend. Its down 0.23, from 1.32 in 2017Q1. 120 funds opened positions while 451 raised stakes. The average revenue per share growth rate of Bristol-Myers Squibb Company during the past 12 months was 12.6 percent. Management Assoc Ny, a New York-based fund reported 4,250 shares. Cypress Capital Management Llc who had been investing in Union Pacific Corp for a number of months, seems to be bullish on the $91.69B market cap company. 59,100 were accumulated by Endowment Mngmt Lp. Tci Wealth Advsrs owns 35,464 shares. Suntrust Banks Incorporated has 706,454 shares. Rock Springs Capital Mngmt Limited Partnership holds 50,000 shares or 0.14% of its portfolio. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets).
River & Mercantile Asset Management LLP bought a new position in Bristol-Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. Boston Common Asset Management Lc holds 96,929 shares. This movement could be bad/good signal for few investors as firm is showing performance for the quarter as 13.46%. Meag Munich Ergo Kapitalanlagegesellschaft Mbh stated it has 113,429 shares.
Bristol-Myers Squibb Company was covered by a number of analysts recently, 6 rated the stock as Buy, 11 rated Hold, 1 rated sell and 1 gave an Underperform. Therefore 32% are positive. Vetr raised shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and set a $67.92 price objective on the stock in a report on Monday, October 9th. The rating was maintained by Barclays Capital on Friday, September 9 with "Equal-Weight".
On October 25, 2017 Citigroup issued a report on BMY and giving a rating of "Buy" and projecting a price target of $72.00. The firm has "Hold" rating given on Monday, August 14 by Cowen & Co. Barclays Capital maintained the shares of BMY in report on Tuesday, December 1 with "Equal Weight" rating.
October 27 investment analysts at Credit Suisse Group left the company rating at "Hold" with a current price target of $61.00. The firm has "Neutral" rating given on Wednesday, August 12 by Goldman Sachs. Wealthtrust Axiom Limited Liability Corp has invested 2.7% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). As per Thursday, August 11, the company rating was downgraded by Berenberg.
Patten & Patten Inc decreased Trinity Industries Inc. (NYSE:FDS) for 70,125 shares. Argi Inv Ltd holds 4,886 shares. American Elec Pwr Inc (NYSE:AEP) was reduced too.
Investors sentiment increased to 1.04 in Q2 2017. Its down 0.03, from 1.15 in 2017Q1.
Gulfport Energy Corporation (NASDAQ:GPOR) ended its day at $13.78 with the rising stream of -2.55% and its total traded volume was 4.21 million shares more than the average volume. 118 funds opened positions while 421 raised stakes.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the company's stock in a transaction that occurred on Wednesday, September 6th. Cornerstone Cap Mgmt Hldg Ltd Liability holds 605,005 shares or 0.56% of its portfolio. Utd Capital Fincl Advisers Ltd Liability Corp invested in 331,874 shares or 0.32% of the stock. D Scott Neal accumulated 3,265 shares or 0.26% of the stock. Auxier Asset Mngmt reported 6,393 shares. (NYSE:PM). Ubs Oconnor Ltd Liability reported 0% stake. Jp Marvel Investment Limited Com holds 89,485 shares or 1.65% of its portfolio. The consensus rating is 2.4, suggesting the market has given up on the stock. Therefore 65% are positive. Cytokinetics had 17 analyst reports since July 24, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with "Buy" rating and $13400 target in Monday, July 17 report. Robert W. Baird maintained it with "Buy" rating and $141.0 target in Thursday, September 7 report. The count of Hold ratings in that period was 10. Cowen & Co maintained Philip Morris International Inc. The rating was maintained by Argus Research with "Buy" on Thursday, November 19. Jefferies maintained the stock with "Hold" rating in Tuesday, September 26 report.